Skip to main content
AVLN logo

AVLN · Avalyn Pharma Inc. · Documents

Track AVLN — free
$28.22 -0.48 (-1.67%)
Market Cap
$1.28B
Shares
44.52M
Volume · Nov 20 42.1K Avg daily vol (3M) 349.44K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Quarterly report FY2026 Q3 Net loss $29.66M 10-Q filed Nov 12, 2026 Latest results AP03 Phase 1 started; cash runway projected into 2029 8-K filed Nov 12, 2026
2026
Nov 18
Investor event
Inhaled APO1 completes enrollment in 52-week Phase 2b study

Avalyn Pharma said its inhaled perfenidone, APO1, completed enrollment in a large global Phase 2b study over the summer, with 52-week data expected in the second half of next year. Its base case is another Phase 3 study before approval. Inhaled nintetanib, APO2, has a 12-week proof-of-concept study with data expected late in 2027.

6 source passages
We have a drug, the inhaled profanedone, APO1, that completed enrollment in a large global Phase 2b study over the summer. It's a 52-week study, so we'll have data back from that in the second half of the year next year. But I think the most conservative plan, the one that we're assuming is our base case, is that we'll have another Phase 3 to do after this for approval. We also have a Phase 2 ongoing for our inhaled nintetinib, that's APO2, Another global phase two study. That one's more of a proof of concept, 12-week study. We think we'll have data back from that program late in 2027. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net loss reaches $85.5 million with runway into 2029

Avalyn Pharma reported a nine-month net loss of $85.5 million and $386.6 million in cash, cash equivalents and marketable securities as of September 30, 2026, which it expects to fund operations into 2029.

Net loss $29.66M Diluted EPS -$0.67
Read from the MD&A section
4 source passages
References to the "Company," “Avalyn,” “Avalyn Pharma” “we,” “our,” “us,” or similar terms refer to Avalyn Pharma Inc. including net losses of $29.7 million and $23.6 million for the three months ended September 30, 2026 and 2025, respectively, and net losses of $85.5 million and $61.3 million for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, we had cash, cash equivalents, and marketable securities of $386.6 million. We believe, based on our current operating plans, that our cash, cash equivalents and investments in marketable securities will enable us to fund our operating expenses and capital expenditures into 2029. Open the document at this passage
Nov 12
Current report 8-K
AP03 Phase 1 started; cash runway projected into 2029

Avalyn Pharma Inc. started a Phase 1 study of AP03 in healthy volunteers. It had $386.6 million in cash, cash equivalents and marketable securities on September 30, 2026, with runway projected into 2029; third-quarter net loss was $29.7 million.

Financial results
4 source passages
BOSTON, MA, November 12, 2026 -- Avalyn Pharma Inc. (Avalyn or the Company, Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases today announced financial results for the third quarter ended September 30, 2026 and recent business highlights. Initiated Phase 1 Trial of AP03 in Healthy Volunteers. Cash, cash equivalents, and marketable securities were $386.6 million as of September 30, 2026. The Company’s current cash, cash equivalents, and marketable securities are projected to be sufficient to fund operations into 2029. Net loss: Net loss was $29.7 million for the third quarter of 2026, as compared to $23.6 million for the third quarter of 2025. Open the document at this passage
Nov 10
Investor event
Avalon says cash supports pipeline into 2029

Avalon said around $400 million of cash extends its runway into 2029, assuming Phase 3 funding for AP01 and AP02. The inhaled profenidone MIST study enrolled 398 patients with progressive pulmonary fibrosis.

5 source passages
Avalon is a clinical stage company. Cash takes us just around $400 million. That takes us into 2029 with the key assumption that our base case will be funding a Phase 3 for AP01 and a Phase 3 for AP02. So the MIS study that you mentioned is our APO-1 inhaled profenadone phase 2B study, designed to be a 375-patient study, but we over-enrolled it. So we completed enrollment ahead of schedule and then over-enrolled. So it's 398 patients in that study. And our MIST study, which is the one that's ongoing now, we think will hopefully really give us powerful data to be able to move the program forward. We're doing it in the sort of second indication in the space, which is called progressive pulmonary fibrosis, or PPF. Open the document at this passage
Showing 1–18 of 18 documents
Key facts CIK 1540171 CUSIP 05348Y105 13F (30d) 112 filings 110 filers Visit website Investor relations